Minelli, Schiavino, Musca, Bruno, Falagiani, Mistrello, Riva, Braga, Turi, Di Rienzo, Petrarca, Schiavone, Di Gioacchino 2010 — Oral hyposensitization to nickel induces clinical improvement and decreases Th1/Th2 cytokines in SNAS
This Int J Immunopathol Pharmacol pilot study from the Italian SNAS-research consortium (Campi Salentina, Gemelli Rome, Spedali Civili Brescia, G. d’Annunzio Chieti, Lofarma Milan) demonstrates that oral hyposensitization to nickel (NiOHT) — graduated oral dosing of nickel sulphate from sub-nanogram to microgram doses over months — produces both clinical improvement and measurable immunological remodeling in SNAS. 36 SNAS patients followed the protocol; both Th1 (IFN-gamma) and Th2 (IL-13, IL-5) cytokine responses to ex-vivo nickel challenge decreased significantly. The paper establishes oral hyposensitization as an alternative to lifelong low-nickel-diet adherence and provides mechanistic immunology supporting the SNAS framework.
Key numbers
Cytokine reductions after NiOHT treatment in SNAS patients:
- IFN-gamma (Th1): -55.3 percent
- IL-13 (Th2): -58.6 percent
- IL-5 (Th2): -31.2 percent
Both Th1 and Th2 pathways are implicated in SNAS; NiOHT downregulates both, consistent with classical oral-tolerance induction mechanisms.
Methods (brief)
Graduated oral nickel sulphate administration starting at very low doses (sub-nanogram) and titrating upward to maintenance over approximately 6 months. Cytokine responses measured by ex-vivo nickel-stimulated peripheral blood mononuclear cell culture at baseline and post-treatment.
Implications
- Certification: Clinical-trial evidence for an alternative to low-Ni-diet for SNAS patients; relevant to vulnerable-population guidance.
- Microbiome / immunology: Direct immunological remodeling of nickel-specific T-cell response; complements the Maier and Benoit 2019 pathogen-virulence framing by addressing the host-immunology side.
- Courses: Standard reference for nickel oral hyposensitization protocol.